Hypertension, antihypertensive treatment and stroke prevention
Despite intensive research efforts, few effective treatments are available once stroke has occurred. Thus, stroke prevention should be a primary focus for all health care provides. The purpose of this article is to review the pathophysiological relevance of hypertension as a leading cause of stroke....
Gespeichert in:
| Veröffentlicht in: | Neurological sciences 2005-05, Vol.26 Suppl 1 (S1), p.S22-s23 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | s23 |
|---|---|
| container_issue | S1 |
| container_start_page | S22 |
| container_title | Neurological sciences |
| container_volume | 26 Suppl 1 |
| creator | Grassi, G Quarti, F Mancia, G |
| description | Despite intensive research efforts, few effective treatments are available once stroke has occurred. Thus, stroke prevention should be a primary focus for all health care provides. The purpose of this article is to review the pathophysiological relevance of hypertension as a leading cause of stroke. This will be followed by an analysis of the evidence that blood pressure lowering with different antihypertensive drugs reduces the risk. Finally recent data suggest that the angiotensin II (ATII)-receptor antagonist losartan may offer advantages beyond blood pressure lowering, including attenuation of the central aortic reflected pressure wave, molecule-specific properties and neural protective influences on brain ATII type 2 receptors. |
| doi_str_mv | 10.1007/s10072-005-0397-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67811391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67811391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-acc0e2d73872e8c1fb26f4efe38c7bc0f232e4b4c86ab39d8f01e286edb9ce213</originalsourceid><addsrcrecordid>eNpdkE9LxDAQxYMo7rr6AbxI8eDJaiZJk_QiyKKusOBFz6FNp9h1-8ckXdhvb8sWBS8zw8x7j-FHyCXQO6BU3fuxspjSJKY8VbE8InNIUhpzofTxNINWYkbOvN9QSkEAPyUzSLTmUos5eVjtO3QBG1-1zW2UNaH6_N3sMAoOs1BjE4ZTEfng2i-MOoe7YTU4zslJmW09Xkx9QT6en96Xq3j99vK6fFzHljMZ4sxaiqxQXCuG2kKZM1kKLJFrq3JLS8YZilxYLbOcp4UuKSDTEos8tciAL8jNIbdz7XePPpi68ha326zBtvdGKg3A01F4_U-4aXvXDL8ZBloKnUg5iOAgsq713mFpOlfVmdsboGZkag5kzUDWjGTN6Lmagvu8xuLPMaHkP8pndPk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218648566</pqid></control><display><type>article</type><title>Hypertension, antihypertensive treatment and stroke prevention</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Grassi, G ; Quarti, F ; Mancia, G</creator><creatorcontrib>Grassi, G ; Quarti, F ; Mancia, G</creatorcontrib><description>Despite intensive research efforts, few effective treatments are available once stroke has occurred. Thus, stroke prevention should be a primary focus for all health care provides. The purpose of this article is to review the pathophysiological relevance of hypertension as a leading cause of stroke. This will be followed by an analysis of the evidence that blood pressure lowering with different antihypertensive drugs reduces the risk. Finally recent data suggest that the angiotensin II (ATII)-receptor antagonist losartan may offer advantages beyond blood pressure lowering, including attenuation of the central aortic reflected pressure wave, molecule-specific properties and neural protective influences on brain ATII type 2 receptors.</description><identifier>ISSN: 1590-1874</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-005-0397-6</identifier><identifier>PMID: 15883684</identifier><language>eng</language><publisher>Italy: Springer Nature B.V</publisher><subject>Angiotensin II Type 2 Receptor Blockers ; Antihypertensive Agents - therapeutic use ; Clinical Trials as Topic ; Humans ; Hypertension - complications ; Hypertension - drug therapy ; Losartan - therapeutic use ; Neurology ; Neurosciences ; Stroke ; Stroke - etiology ; Stroke - prevention & control</subject><ispartof>Neurological sciences, 2005-05, Vol.26 Suppl 1 (S1), p.S22-s23</ispartof><rights>Springer-Verlag Italia 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-acc0e2d73872e8c1fb26f4efe38c7bc0f232e4b4c86ab39d8f01e286edb9ce213</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15883684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grassi, G</creatorcontrib><creatorcontrib>Quarti, F</creatorcontrib><creatorcontrib>Mancia, G</creatorcontrib><title>Hypertension, antihypertensive treatment and stroke prevention</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><description>Despite intensive research efforts, few effective treatments are available once stroke has occurred. Thus, stroke prevention should be a primary focus for all health care provides. The purpose of this article is to review the pathophysiological relevance of hypertension as a leading cause of stroke. This will be followed by an analysis of the evidence that blood pressure lowering with different antihypertensive drugs reduces the risk. Finally recent data suggest that the angiotensin II (ATII)-receptor antagonist losartan may offer advantages beyond blood pressure lowering, including attenuation of the central aortic reflected pressure wave, molecule-specific properties and neural protective influences on brain ATII type 2 receptors.</description><subject>Angiotensin II Type 2 Receptor Blockers</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Losartan - therapeutic use</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Stroke</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><issn>1590-1874</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkE9LxDAQxYMo7rr6AbxI8eDJaiZJk_QiyKKusOBFz6FNp9h1-8ckXdhvb8sWBS8zw8x7j-FHyCXQO6BU3fuxspjSJKY8VbE8InNIUhpzofTxNINWYkbOvN9QSkEAPyUzSLTmUos5eVjtO3QBG1-1zW2UNaH6_N3sMAoOs1BjE4ZTEfng2i-MOoe7YTU4zslJmW09Xkx9QT6en96Xq3j99vK6fFzHljMZ4sxaiqxQXCuG2kKZM1kKLJFrq3JLS8YZilxYLbOcp4UuKSDTEos8tciAL8jNIbdz7XePPpi68ha326zBtvdGKg3A01F4_U-4aXvXDL8ZBloKnUg5iOAgsq713mFpOlfVmdsboGZkag5kzUDWjGTN6Lmagvu8xuLPMaHkP8pndPk</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Grassi, G</creator><creator>Quarti, F</creator><creator>Mancia, G</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>Hypertension, antihypertensive treatment and stroke prevention</title><author>Grassi, G ; Quarti, F ; Mancia, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-acc0e2d73872e8c1fb26f4efe38c7bc0f232e4b4c86ab39d8f01e286edb9ce213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Angiotensin II Type 2 Receptor Blockers</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Losartan - therapeutic use</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Stroke</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grassi, G</creatorcontrib><creatorcontrib>Quarti, F</creatorcontrib><creatorcontrib>Mancia, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grassi, G</au><au>Quarti, F</au><au>Mancia, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypertension, antihypertensive treatment and stroke prevention</atitle><jtitle>Neurological sciences</jtitle><addtitle>Neurol Sci</addtitle><date>2005-05</date><risdate>2005</risdate><volume>26 Suppl 1</volume><issue>S1</issue><spage>S22</spage><epage>s23</epage><pages>S22-s23</pages><issn>1590-1874</issn><eissn>1590-3478</eissn><abstract>Despite intensive research efforts, few effective treatments are available once stroke has occurred. Thus, stroke prevention should be a primary focus for all health care provides. The purpose of this article is to review the pathophysiological relevance of hypertension as a leading cause of stroke. This will be followed by an analysis of the evidence that blood pressure lowering with different antihypertensive drugs reduces the risk. Finally recent data suggest that the angiotensin II (ATII)-receptor antagonist losartan may offer advantages beyond blood pressure lowering, including attenuation of the central aortic reflected pressure wave, molecule-specific properties and neural protective influences on brain ATII type 2 receptors.</abstract><cop>Italy</cop><pub>Springer Nature B.V</pub><pmid>15883684</pmid><doi>10.1007/s10072-005-0397-6</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-1874 |
| ispartof | Neurological sciences, 2005-05, Vol.26 Suppl 1 (S1), p.S22-s23 |
| issn | 1590-1874 1590-3478 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67811391 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Angiotensin II Type 2 Receptor Blockers Antihypertensive Agents - therapeutic use Clinical Trials as Topic Humans Hypertension - complications Hypertension - drug therapy Losartan - therapeutic use Neurology Neurosciences Stroke Stroke - etiology Stroke - prevention & control |
| title | Hypertension, antihypertensive treatment and stroke prevention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T18%3A49%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypertension,%20antihypertensive%20treatment%20and%20stroke%20prevention&rft.jtitle=Neurological%20sciences&rft.au=Grassi,%20G&rft.date=2005-05&rft.volume=26%20Suppl%201&rft.issue=S1&rft.spage=S22&rft.epage=s23&rft.pages=S22-s23&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-005-0397-6&rft_dat=%3Cproquest_cross%3E67811391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218648566&rft_id=info:pmid/15883684&rfr_iscdi=true |